Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma.

Frontiers in immunology - 1 Jan 2022

Yan Dongming, Li Weicheng, Liu Qibing, Yang Kun

Abstract excerpt

The tumor immune microenvironment and immunotherapy have become current important tumor research concerns. The unique immune microenvironment plays a crucial role in the malignant progression of isocitrate dehydrogenase (IDH) mutant gliomas. IDH mutations in glioma can inhibit tumor-associated immune system evasion of NK cell immune surveillance. Meanwhile, mutant IDH can inhibit classical and alternative...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Glioma
Share to Glioma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunologic Factors

Share to Immunotherapy

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 35769466
DOI: 10.3389/fimmu.2022.914618
PMCID: PMC9234270

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma.PMID 35769466Read ↗

Advances in the Immunotherapeutic Potential of Isocitrate Dehydrogenase Mutations in Glioma.Semantic proximity Read ↗

Potential of IDH mutations as immunotherapeutic targets in gliomas: a review and meta-analysis.Semantic proximity Read ↗

Perspectives of immunotherapy in isocitrate dehydrogenase-mutant gliomas.Semantic proximity Read ↗

Implications of IDH mutations on immunotherapeutic strategies for malignant glioma.Semantic proximity Read ↗

Deciphering diffuse glioma immune microenvironment as a key to improving immunotherapy results.Semantic proximity Read ↗

The immunology of low-grade gliomas.Semantic proximity Read ↗

Illuminating the cross-talk between tumor metabolism and immunity in IDH-mutated cancers.Semantic proximity Read ↗

Immunotherapy Approaches in Isocitrate-Dehydrogenase-Mutant Low-Grade GliomaSemantic proximity Read ↗

Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomasSemantic proximity Read ↗

D-2-Hydroxyglutarate Is an Intercellular Mediator in IDH-Mutant Gliomas Inhibiting Complement and T Cells.Semantic proximity Read ↗

Molecular and clinical characterization of IDH associated immune signature in lower-grade gliomasSemantic proximity Read ↗

A specific immune signature for predicting the prognosis of glioma patients with IDH1-mutation and guiding immune checkpoint blockade therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.